Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Equipment and Improvements

3 Months Ended

Mar. 31, 2023


Equipment and Improvements, net
	March 31,		December 31,
	2023		2022
Furniture and office equipment	$	72,692	$	72,692
Lab equipment		153,668		153,668
IT equipment		16,895		16,895
		243,255		243,255
Less: Accumulated Depreciation		11,766		6,723
Total	$	231,489	$	236,532

Depreciation expense for the period ended March 31, 2023 was $5,043 and for year ended December 31, 2022 was $6,723.